529 related articles for article (PubMed ID: 19318323)
21. Lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors): pathology, prognosis, and proposed classification.
McKenney JK; Balzer BL; Longacre TA
Am J Surg Pathol; 2006 May; 30(5):614-24. PubMed ID: 16699316
[TBL] [Abstract][Full Text] [Related]
22. Assessing the landscape of ovarian serous borderline tumors.
Messini I; Doulgeraki T; Chrysanthakis D; Yiannou P; Gavresea T; Papadimitriou C; Panoskaltsis T; Voulgaris Z; Vlachos A; Pavlakis K
Int J Gynecol Cancer; 2019 Mar; 29(3):572-578. PubMed ID: 30659030
[TBL] [Abstract][Full Text] [Related]
23. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors.
Lu KH; Bell DA; Welch WR; Berkowitz RS; Mok SC
Cancer Res; 1998 Jun; 58(11):2328-30. PubMed ID: 9622067
[TBL] [Abstract][Full Text] [Related]
24. Hobnail-like cells in serous borderline tumor do not represent concomitant incipient clear cell neoplasms.
Ohishi Y; Oda Y; Kurihara S; Kaku T; Yasunaga M; Nishimura I; Okuma E; Kobayashi H; Wake N; Tsuneyoshi M
Hum Pathol; 2009 Aug; 40(8):1168-75. PubMed ID: 19368953
[TBL] [Abstract][Full Text] [Related]
25. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis.
Sherman ME; Mink PJ; Curtis R; Cote TR; Brooks S; Hartge P; Devesa S
Cancer; 2004 Mar; 100(5):1045-52. PubMed ID: 14983501
[TBL] [Abstract][Full Text] [Related]
26. Fascin expression in serous tumors of ovary correlates with aggressiveness of malignancy.
Wen YH; Yee H; Goswami S; Shukla PS
Int J Gynecol Pathol; 2009 Mar; 28(2):187-92. PubMed ID: 19188814
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas.
Shappell HW; Riopel MA; Smith Sehdev AE; Ronnett BM; Kurman RJ
Am J Surg Pathol; 2002 Dec; 26(12):1529-41. PubMed ID: 12459620
[TBL] [Abstract][Full Text] [Related]
28. Results after conservative treatment of serous borderline tumors of the ovary with a micropapillary pattern.
Laurent I; Uzan C; Gouy S; Pautier P; Duvillard P; Morice P
Ann Surg Oncol; 2008 Dec; 15(12):3561-6. PubMed ID: 18820973
[TBL] [Abstract][Full Text] [Related]
29. Borderline tumors of the ovary and peritoneal implants.
Denkert C; Dietel M
Verh Dtsch Ges Pathol; 2005; 89():84-91. PubMed ID: 18035677
[TBL] [Abstract][Full Text] [Related]
30. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
[TBL] [Abstract][Full Text] [Related]
31. Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum.
Seidman JD; Horkayne-Szakaly I; Cosin JA; Ryu HS; Haiba M; Boice CR; Yemelyanova AV
Gynecol Oncol; 2006 Nov; 103(2):703-8. PubMed ID: 16828848
[TBL] [Abstract][Full Text] [Related]
32. [Clinical and pathological features of borderline ovarian tumors].
Li Y; Cui H; Shen DH; Zhao Y; Wei LH; Qian HN
Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):81-4. PubMed ID: 12783693
[TBL] [Abstract][Full Text] [Related]
33. Molecular genetic evidence of an independent origin of serous low malignant potential implants and lymph node inclusions.
Emerson RE; Wang M; Liu F; Lawrence WD; Abdul-Karim FW; Cheng L
Int J Gynecol Pathol; 2007 Oct; 26(4):387-94. PubMed ID: 17885488
[TBL] [Abstract][Full Text] [Related]
34. The relationship between papillary infarction and microinvasion in ovarian atypical proliferative ("borderline") serous and seromucinous tumors.
Kraus JA; Seidman JD
Int J Gynecol Pathol; 2010 Jul; 29(4):303-9. PubMed ID: 20567140
[TBL] [Abstract][Full Text] [Related]
35. Bilateral micropapillary serous carcinoma of the ovary: a case report.
Gupta R; Singh S; Nigam S
Arch Gynecol Obstet; 2007 May; 275(5):401-4. PubMed ID: 17031658
[TBL] [Abstract][Full Text] [Related]
36. Microdissection-based mutational genotyping of serous borderline tumors of the ovary.
Krishnamurti U; Sasatomi E; Swalsky PA; Jones MW; Finkelstein SD
Int J Gynecol Pathol; 2005 Jan; 24(1):56-61. PubMed ID: 15626917
[TBL] [Abstract][Full Text] [Related]
37. Papillary serous carcinoma in ovaries of normal size: a clinicopathologic study of 20 cases and comparison with extraovarian peritoneal papillary serous carcinoma.
Choi CH; Kim TJ; Kim WY; Ahn GH; Lee JW; Kim BG; Lee JH; Bae DS
Gynecol Oncol; 2007 Jun; 105(3):762-8. PubMed ID: 17383715
[TBL] [Abstract][Full Text] [Related]
38. [Ovarian tumors of low malignant potential (borderline ovarian tumors)].
Luchian AM; Pricop M
Rev Med Chir Soc Med Nat Iasi; 2011; 115(2):438-45. PubMed ID: 21870737
[TBL] [Abstract][Full Text] [Related]
39. [Diagnostic problems of ovarian mucinous borderline tumors].
Vereczkey I; Tóth E; Orosz Z
Magy Onkol; 2009 Jun; 53(2):127-33. PubMed ID: 19581178
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant platinum-based chemotherapy for borderline serous ovarian tumors with invasive implants.
Leary A; Petrella MC; Pautier P; Duvillard P; Uzan C; Tazi Y; Ledoux F; Gouy S; Morice P; Lhommé C
Gynecol Oncol; 2014 Jan; 132(1):23-7. PubMed ID: 24219980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
